Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 45Gastrointestinal 8Gynecologic 4Breast 4Sarcoma 2Head & Neck 2Genitourinary 2Endocrine 1CNS 1

Conditions

Head and Neck Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Optic Nerve Glioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1

Interventions

pembrolizumab 17Nivolumab 6Docetaxel 6Gemcitabine 5Cisplatin 5Carboplatin 5durvalumab 4Paclitaxel 4Ipilimumab 4avelumab 3atezolizumab 3Filgrastim 3Cyclophosphamide 3Bortezomib 3130-nm albumin-bound paclitaxel 3tremelimumab 2tislelizumab 2spartalizumab 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2abiraterone 2Radiotherapy 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Nicotine 2Irinotecan 2Interleukin-2 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Irinotecan × Head & Neck × Clear all
NCT04640480 2026-01-27

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

SN BioScience

Phase 1 Completed
21 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡